Skip to main content

Table 1 Patients’ characteristics (25 allo-HSCT patients)

From: Unmasking viral sequences by metagenomic next-generation sequencing in adult human blood samples during steroid-refractory/dependent graft-versus-host disease

  Total
n = 25
Demographics
 Sex (male), n (%) 16 (64.0)
 Age, median (IQR) 58.0 (25.0)
Allo-HSCT considered in the analysis, n (%)
 First 23 (92.0)
 Second 2 (8.0)
Transplant source, n (%)
 Bone marrow 5 (20)
 Peripheral blood cells 20 (80)
Underlying disease, n (%)
 Acute myeloid leukemia 10 (40.0)
 Lymphoid malignancy 6 (24.0)
 MDS/MDPS 3 (12.0)
 Acute lymphoid leukemia 2 (8.0)
 Othera 4 (16.0)
Risk score, n (%)
 Low 0 (0)
 Intermediate 18 (72.0)
 High 7 (28.0)
Donor sex, M, n (%) 7 (28.0)
Donor age, median (IQR) 36 (16.5)
Donor match, n (%)
 Donor-related 10 (40.0)
CMV donor/recipient constellation, n (%)
 +/+ 12 (48.0)
 −/+ 1 (4.0)
 +/− 7 (28.0)
 −/− 5 (20.0)
CMV prophylaxis, n (%) 1 (4.0)
Conditioning, n (%)
 Myeloablative conditioning 5 (20.0)
GvHD prophylaxis, n (%)
 Calcineurin inhibitor 24 (96.0)
 Mycophenolate mofetil 17 (68.0)
 Methotrexate 7 (28.0)
GvHD organ, n (%)
 Digestive tract 17 (68.0)
 Skin 15 (60.0)
 Mouth 4 (16.0)
 Liver 7 (28.0)
 Lung 5 (20.0)
 Eyes 2 (8.0)
 Musculoskeletal 1 (4.0)
GvHD grade or severity, n (%)
 Grade
  2 9 (36.0)
  3 3 (12.0)
  4 6 (24.0)
 Moderate 6 (24.0)
 Severe 7 (28.0)
GvHD treatment, n (%)
 Corticosteroids 24 (96.0)
 Ruxolitinib 22 (88.0)
 Calcineurin inhibitor 21 (84.0)
 Mycophenolate mofetil 12 (48.0)
 Photopheresis 12 (48.0)
 Budenoside 5 (20.0)
 Sirolimus 3 (12.0)
 Tocilizumab 2 (8.0)
 Otherb 6 (24.0)
Death, n (%) 15 (60.0)
 Median delay from allo-HSCT, months (IQR) 11.2 (15.8)
  1. One patient could have multiple GvHD prophylaxis and treatment, multiple organs with GvHD and multiple grades of severity. CMV prophylaxis: one patient (patient Ge24) received letermovir during the period of intensive steroid treatment or second-line GvHD therapy. GvHD grade refers to acute GvHD, GvHD severity refers to chronic GvHD. In two patients, there was no information on grade/severity. Only organs with grade GvHD ≥ 2 or severity ≥ moderate are reported
  2. Abbreviations: IQR interquartile range, allo-HSCT allogeneic hematopoietic stem cell transplantation, MDS/MDPS myelodysplasic syndrome/myelodysplasic proliferative syndrome, ATG anti-thymocyte globulin
  3. aOther includes: multiple myeloma (n = 2), chronic myeloid leukemia (n = 1) and mixed acute leukemia (n = 1)
  4. bOther includes: azithromycine, montelukast, prolastin, vedolisumab, nilotinib, basilixumab, ibrutinib, and/or methotrexate
\